Alex Andrianopoulos
Director/Board Member at Kapteyn-Murnane Laboratories, Inc.
Profile
Alex Andrianopoulos is currently a Director at Kapteyn-Murnane Laboratories, Inc., Applaud Medical, Inc., Novosteo, Inc., Stoicheia, Inc., Vivodyne, Inc., and NVasc, Inc.
Alex Andrianopoulos active positions
Companies | Position | Start |
---|---|---|
Kapteyn-Murnane Laboratories, Inc.
Kapteyn-Murnane Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Kapteyn-Murnane Laboratories, Inc. manufactures laser and amplified systems and fiber lasers. Its products include extreme ultraviolet sources, vacuum ultraviolet source, integrated systems, ultrafast TI:s laser, fiber lasers and measurement products. The company was founded by Henry C. Kapteyn and Margaret M. Murnane in November 1994 and is headquartered in Boulder, CO. | Director/Board Member | - |
Vivodyne, Inc.
Vivodyne, Inc. Packaged SoftwareTechnology Services Vivodyne, Inc. is a biotechnology company based in Philadelphia, PA. Vivodyne accelerates the development of more effective medicines by testing on thousands of lifelike, lab-grown human organ tissues at a time. The company uses robots to grow and experiment on lab-grown human organs at a massive scale, creating datasets of unparalleled realism and breadth to power a predictive AI platform technology. Vivodyne's platform powers the entire discovery pipeline by testing drugs on thousands of lab-grown human tissues with complete robotic automation, accelerating the discovery of cures to human diseases by creating predictive, preclinical human data. The company was founded by Andrei Georgescu and Dan Huh, with Andrei Georgescu serving as the CEO since incorporation. | Director/Board Member | - |
NVasc, Inc.
NVasc, Inc. Medical SpecialtiesHealth Technology NVasc, Inc. is an early-stage ophthalmology company founded in February 2019 and funded by Kairos Ventures in November 2019. The company is based in Atherton, CA. The company is focused on treating the leading causes of blindness through choroidal and retinal revascularization. The company is planning to manufacture NVB001 that can be used in toxicokinetic studies and in early clinical trials in humans. NVasc has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. | Director/Board Member | - |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | Director/Board Member | - |
Stoicheia, Inc.
Stoicheia, Inc. Miscellaneous Commercial ServicesCommercial Services Stoicheia, Inc. is a company based in Suite 330, IL that specializes in digital materials discovery. Stoicheia uses a combination of proprietary AI and high-throughput screening technology to discover new materials that impact industries such as automotive, chemical, oil, and clean energy. The company has access to the world's largest combinatorial material libraries and uses proprietary nanocombinatoricstm and megalibrarytm platforms to enable the discovery of new materials with properties driving the development of the renewable and net-zero economy. The company was founded by Chad A. Mirkin and Andrey Ivankin, and Jeff Erhardt has been the CEO of the company since 2023. | Director/Board Member | - |
Applaud Medical, Inc.
Applaud Medical, Inc. Medical SpecialtiesHealth Technology Applaud Medical, Inc. engages in the development of medical devices for kidney stone treatment. The company was founded by Thomas William Kenny, Jr. and Claire Mills in 2014 and is headquartered in San Francisco, CA. | Director/Board Member | - |
Former positions of Alex Andrianopoulos
Companies | Position | End |
---|---|---|
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Director/Board Member | - |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
Private companies | 7 |
---|---|
Kapteyn-Murnane Laboratories, Inc.
Kapteyn-Murnane Laboratories, Inc. Miscellaneous Commercial ServicesCommercial Services Kapteyn-Murnane Laboratories, Inc. manufactures laser and amplified systems and fiber lasers. Its products include extreme ultraviolet sources, vacuum ultraviolet source, integrated systems, ultrafast TI:s laser, fiber lasers and measurement products. The company was founded by Henry C. Kapteyn and Margaret M. Murnane in November 1994 and is headquartered in Boulder, CO. | Commercial Services |
Actuate Therapeutics, Inc.
Actuate Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Actuate Therapeutics, Inc. is a clinical stage biopharmaceutical company, which engages in developing therapeutics which target cancers and neurodegenerative diseases. It offers treatment for cancer and inflammatory diseases. It focuses on developing elraglusib. The company was founded by Andrew P. Mazar on January 16, 2015 and is headquartered in Fort Worth, TX. | Health Technology |
Applaud Medical, Inc.
Applaud Medical, Inc. Medical SpecialtiesHealth Technology Applaud Medical, Inc. engages in the development of medical devices for kidney stone treatment. The company was founded by Thomas William Kenny, Jr. and Claire Mills in 2014 and is headquartered in San Francisco, CA. | Health Technology |
Novosteo, Inc.
Novosteo, Inc. Pharmaceuticals: MajorHealth Technology Novosteo, Inc. develops drug to reduce complications from a broken bone. The company was founded by Stewart A. Low and Philips S. Low in 2017 and is headquartered in West Lafayette, IN. | Health Technology |
Stoicheia, Inc.
Stoicheia, Inc. Miscellaneous Commercial ServicesCommercial Services Stoicheia, Inc. is a company based in Suite 330, IL that specializes in digital materials discovery. Stoicheia uses a combination of proprietary AI and high-throughput screening technology to discover new materials that impact industries such as automotive, chemical, oil, and clean energy. The company has access to the world's largest combinatorial material libraries and uses proprietary nanocombinatoricstm and megalibrarytm platforms to enable the discovery of new materials with properties driving the development of the renewable and net-zero economy. The company was founded by Chad A. Mirkin and Andrey Ivankin, and Jeff Erhardt has been the CEO of the company since 2023. | Commercial Services |
Vivodyne, Inc.
Vivodyne, Inc. Packaged SoftwareTechnology Services Vivodyne, Inc. is a biotechnology company based in Philadelphia, PA. Vivodyne accelerates the development of more effective medicines by testing on thousands of lifelike, lab-grown human organ tissues at a time. The company uses robots to grow and experiment on lab-grown human organs at a massive scale, creating datasets of unparalleled realism and breadth to power a predictive AI platform technology. Vivodyne's platform powers the entire discovery pipeline by testing drugs on thousands of lab-grown human tissues with complete robotic automation, accelerating the discovery of cures to human diseases by creating predictive, preclinical human data. The company was founded by Andrei Georgescu and Dan Huh, with Andrei Georgescu serving as the CEO since incorporation. | Technology Services |
NVasc, Inc.
NVasc, Inc. Medical SpecialtiesHealth Technology NVasc, Inc. is an early-stage ophthalmology company founded in February 2019 and funded by Kairos Ventures in November 2019. The company is based in Atherton, CA. The company is focused on treating the leading causes of blindness through choroidal and retinal revascularization. The company is planning to manufacture NVB001 that can be used in toxicokinetic studies and in early clinical trials in humans. NVasc has acquired the research rights to growth factors (NVB001 and NVB002) that have been shown to encourage the growth of non-leaking new vessels in the retina and choroid in mouse models of ischemic eye diseases. | Health Technology |
- Stock Market
- Insiders
- Alex Andrianopoulos